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Background/Aims: For unknown reasons, caspase-1 -/- mice, protected against cisplatin-induced acute renal failure 
(ARF), are deficient in interleukin (IL)-1α. We thus asked whether IL-1α deficiency underlies the mechanism of protection 
against cisplatin-induced ARF in these mice.
Methods: Cisplatin (30 mg/kg) was injected intraperitoneally into wild-type C57BL/6 mice to produce a cisplatin-induced 
model of ARF. IL-1α was measured in control vehicle- and cisplatin-treated wild-type animals. We also examined whether 
IL-1α -/- mice were similarly protected against cisplatin-induced ARF. Additionally, infiltration of CD11b- and CD49b-positive 
cells, as markers of macrophages, natural killer, and natural killer T cells (pan-NK cells), was investigated in wild-type and 
IL-1α -/- mice.
Results: Compared with vehicle-treated mice, renal IL-1α increased in cisplatin-treated wild-type mice beginning on day 
1. IL-1α -/- mice were shown to be protected against cisplatin-induced ARF. No significant difference in the infiltration of 
neutrophils or CD11b- and CD49b-positive cells were observed between wild-type and IL-1α -/- mice.
Conclusions: Mice deficient in IL-1α are protected against cisplatin-induced ARF. The lack of IL-1α may explain, at 
least in part, the protection against cisplatin-induced ARF observed in caspase-1 -/- mice. Investigation of the protective 
mechanism (s) in IL-1α -/- mice in cisplatin-induced ARF merits further study. (Korean J Intern Med 2011;26:187-194)
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INTRODUCTION
The potent antineoplastic agent cisplatin is highly 
nephrotoxic and is known to cause acute renal failure 
(ARF), which limits its use as a chemotherapeutic agent 
[1]. As one of the most widely studied nephrotoxins, the 
pathogenesis of cisplatin-induced ARF has been the focus 
of several studies, with the goal of developing adjunctive 
therapies.
In vitro, cisplatin causes apoptosis or necrosis of 
renal proximal tubular cells, depending on the dose [2]. 
In vivo, histological studies have shown apoptosis and 
necrosis as well as inflammation of renal tissue [3-7]. 
Proinflammatory effects in cisplatin-induced ARF have 
been well-documented and include increases in the mRNA 
levels of proinflammatory cytokines, adhesion molecules, 
and chemokines [3,8]. Accordingly, anti-inflammatory 
strategies have been developed to inhibit cisplatin-
induced ARF, such as anti-TNF-α [3,4], interleukin (IL)-
10 [5], and anti-intercellular adhesion molecule-1 (ICAM-
1) [6]. Faubel et al. [9] demonstrated that renal caspase-1 
activity was increased in cisplatin-induced ARF and 
that renal dysfunction, tubular necrosis, and neutrophil 
infiltration were reduced in caspase-1 -/- mice. Caspase-1 
converts the precursor forms of the proinflammatory 
cytokines IL-1b and IL-18 to their mature forms [10,11]. It 
was thus suggested that caspase-1 -/- mice are protected 
against cisplatin-induced ARF because of a reduction in 
these proinflammatory cytokines and in renal neutrophil 
infiltration [9]. However, prevention of the increases in 
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renal IL-1b, IL-18, and neutrophils is insufficient to inhibit 
cisplatin-induced ARF [10].
Although IL-1α is not a known substrate of caspase-1, it 
has been observed that caspase-1 -/- mice are also deficient 
in IL-1α [11]. Because the findings regarding IL-1b, IL-18, 
and neutrophil inhibition were negative, we asked whether 
the IL-1α deficiency could explain the protection of 
caspase-1 -/- mice against cisplatin-induced ARF and thus 
whether this cytokine played a role in the pathogenesis of 
the disease.
METHODS
Animals and drug administration
IL-1α -/- mice were provided by Dr. Yichiro Iwakura of 
the Institute of Medical Science at the University of Tokyo, 
Japan. IL-1α deficiency was confirmed by enhanced 
chemiluminescence for IL-1α in the spleen and kidney 
(Fig. 1). Age-matched C57BL/6 mice (Harlan, Indianapolis, 
IN and Jackson Labs, Bar Harbor, ME, USA) weighing 20-
25 g were used as controls for IL-1α -/- mice.
Cisplatin-induced ARF
Mice were maintained on a standard diet and water 
was freely available. Animals were housed five to a cage 
under a 12/12-hour light/dark schedule for at least 1 week 
before cisplatin treatment. Food and water were withheld 
for 12 hours prior to administration of the drug. Cisplatin 
was injected intraperitoneally at a dose of 30 mg/kg, 
after which the mice again had free access to food and 
water. The mice were anesthetized with Avertin (2, 2, 
2-tribromoethanol; Aldrich, Milwaukee, WI, USA) and 
their kidneys then removed. Additionally, blood samples 
were collected via cardiac puncture 1, 2, or 3 days after 
cisplatin administration.
Drug preparation
Cisplatin (Aldrich) was prepared freshly on the day of 
administration in normal saline at a concentration of 1 
mg/mL. Mice were given either 30 mg cisplatin/kg body 
weight or the same volume of vehicle (Veh; saline).
Blood urea nitrogen and serum creatinine 
measurements
Blood urea nitrogen (BUN) and serum creatinine were 
measured using a BUN and creatinine autoanalyzer 
(Beckman Instruments, Fullerton, CA, USA).
Enhanced chemiluminescence assay for IL-1α
The enhanced chemiluminescence assay, detecting both 
the precursor and mature forms of IL-1α, was performed 
using whole-kidney homogenates as described previously 
in detail [12].
Histological acute tubular necrosis (ATN), 
apoptosis scoring, and neutrophil infiltration
Kidneys fixed in 4% paraformaldehyde and paraffin-
embedded were sectioned at 4 μm and stained with 
periodic acid-Schiff (PAS) by standard methods. All 
histological examinations were performed by a renal 
pathologist in a blinded fashion. Histological changes 
due to ATN were evaluated in the outer strip of the outer 
medulla on PAS-stained tissue and quantified by counting 
the proportion of tubules that displayed cell necrosis, 
brush-border loss, cast formation, and tubule dilation, 
as follows: 0, none; 1, < 10%; 2, 11-25%; 3, 26-45%; 4, 
46-75%; and 5, > 76%. At least 10 fields (× 200) were 
reviewed on each slide. Morphological criteria, including 
cellular rounding and shrinkage, nuclear chromatin 
compaction, and the formation of apoptotic bodies, were 
used to determine apoptotic cells on PAS-stained tissue. 
Cells were counted by a pathologist experienced in the 
evaluation of renal apoptosis. Apoptotic tubular cells were 
quantitatively assessed per high-powered field in the 
outer strip of the outer medulla by a renal pathologist in 
a blinded fashion. At least 10 fields were counted on each 
slide. Neutrophil infiltration was assessed quantitatively 
on PAS-stained tissue by a renal pathologist by counting 
the number of neutrophils per high-powered field (× 400). 
Figure 1. Confirmation of interleukin (IL)-1α deficiency in IL-
1α -/- mice ( 
a  p < 0.05 vs. C57BL/6 wild-type mice, n = 6).Lee JW, et al. IL-1α in cisplatin-induced ARF    189
At least 10 fields comprising the outer strip of the outer 
medulla were counted on each slide.
Immunofluorescence for CD11b-positive cells as a 
marker of macrophages and CD49b-positive cells 
as a marker of pan-NK cells
Kidney tissues were embedded in optimal cutting 
temperature medium, snap-frozen in liquid nitrogen, and 
stored at -80°C until sectioning. Cryostat sections (5 μm) 
were fixed in 70% acetone/30% methanol and prepared 
for immunofluorescence studies as described previously 
[13]. The primary antibodies used were rat anti-mouse 
CD11b monoclonal antibody (catalog no. MCA74; Serotec, 
Oxford, UK), as a macrophage marker, and purified anti-
mouse CD49b (pan-NK cells; BioLegend, San Diego, CA, 
USA), for the determination of pan-NK cell infiltration. 
Fifteen randomly chosen high-powered fields (× 400) of 
the corticomedullary junction were assessed by a renal 
pathologist in a blinded fashion.
Statistical analyses
Values are expressed as the mean ± SE. Non-normally 
distributed data were analyzed by the non-parametric 
unpaired Mann-Whitney test. Multiple-group comparisons 
were assessed by the Kruskal-Wallis test using the post 
hoc Newman-Keuls test. p values < 0.05 were considered 
to indicate statistical significance.
RESULTS
Renal function in cisplatin-induced ARF
Renal dysfunction was most severe on day 3 whereas 
on days 1 and day 2 serum creatinine (Cr) and BUN were 
unchanged after cisplatin injection. On day 1, serum 
BUN and Cr (mg/dL) were 26.6 ± 3.3 and 0.5 ± 0.1 in the 
cisplatin-treated (Cis) group (p > 0.05 vs. Veh; BUN/Cr: 
22.6 ± 3.0 and 0.3 ± 0.1; n = 15). On day 2, serum BUN 
and Cr were 46.2 ± 17.7 and 0.4 ± 0.2 in the Cis group (p > 
0.05 vs. Veh, day 1; n = 15). On day 3, serum BUN and Cr 
were 222.0 ± 82.9 and 3.3 ± 1.7 in the Cis group (p < 0.001 
vs. Veh, day 1, day 2; n = 15).
Figure 2. Renal interleukin (IL)-1α levels in cisplatin-induced 
acute renal failure. Renal IL-1α was determined on days 1, 2, and 
3 in vehicle (Veh)- and cisplatin (Cis)-treated wild-type mice. Re-
nal IL-1α was higher in cisplatin-treated than in vehicle-treated 
wild-type mice on days 1, 2, and 3 ( 
a,b,c p < 0.05 vs. vehicle-treated 
wild type mice, n = 6).
Figure 3. Renal function in cisplatin-treated interleukin (IL)-
1α -/- mice. By day 3 of cisplatin injection, blood urea nitrogen 
(BUN) and creatinine level (mg/dL) had increased significantly 
in cisplatin-treated wild-type mice ( 
a,b,cp < 0.05 vs. vehicle-
treated wild-type and IL-1α -/- mice, cisplatin-treated IL-1α -/- 
mice, n = 15) and cisplatin-treated IL-1α -/- mice ( 
d,ep < 0.05 vs. 
vehicle-treated wild-type and IL-1α -/- mice, n = 15). Also, there 
was a significant difference in BUN and creatinine level (mg/dL) 
between cisplatin-treated wild-type and cisplatin-treated IL-1α 
-/- mice (178 ± 16 and 2.2 ± 0.3 vs. 102 ± 12 and 1.5 ± 0.4; p < 0.05; 
n = 15). ARF, acute renal failure.
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Renal IL-1α in cisplatin-induced ARF
Renal IL-1α was determined on days 1, 2, and 3 in 
vehicle- and cisplatin-treated wild-type mice. Compared 
with the vehicle-treated wild-type control, renal IL-1α 
increased on all 3 days in cisplatin-treated wild-type mice 
(n = 6; Fig. 2).
Renal function in cisplatin-treated IL-1α -/- mice
IL-1α -/- mice were studied to investigate the role of IL-
1α in cisplatin-induced ARF. Fig. 3 shows that BUN and 
Cr levels increased significantly in cisplatin- vs.vehicle-
treated wild-type and IL-1α -/- mice (178 ± 16, 2.2 ± 0.3 
vs. 22 ± 3, 0.2 ± 0.1; 25 ± 3, 0.2 ± 0.1, p < 0.05, n = 15). 
Additionally, there was a significant difference in the BUN 
and Cr levels of cisplatin-treated wild-type and cisplatin-
treated IL-1α -/- mice (178 ± 16 and 2.2 ± 0.3 vs. 102 ± 12 
and 1.5 ± 0.4; p < 0.05, n = 15).
Acute tubular necrosis, apoptosis, and neutrophil 
score in cisplatin-treated IL-1α -/- mice
ATN scores increased significantly in cisplatin- vs. 
vehicle-treated wild type and IL-1α -/- mice (4.7 ± 0.2 vs. 
0.3 ± 0.1, 0.2 ± 0.1, p < 0.05; n = 15; Fig. 4). A significant 
difference in the ATN scores of cisplatin-treated wild-type 
and IL-1α -/- mice was also noted (4.7 ± 0.2 vs. 3.3 ± 0.2; 
p < 0.05, n = 15). The number of apoptotic tubular cells 
per 10 high-powered fields was 0.2 ± 0.1 in vehicle-treated 
wild-type and IL-1α -/- mice, 13 ± 6 in cisplatin-treated 
wild-type mice, and 13 ± 4 in cisplatin-treated IL-1α -/- 
mice (n = 15). Neutrophil scores were significantly higher 
in cisplatin-treated wild-type mice than in vehicle-treated 
wild-type and IL-1α -/- mice (98.7 ± 15.1 vs. 1.3 ± 0.2 vs. 
1.7 ± 0.2, p < 0.05; n = 15; Fig. 5). However, there was no 
significant difference in the neutrophil scores of cisplatin-
treated wild-type and IL-1α -/- mice (98.7 ± 15.1 vs. 90.7 ± 
12.5; p > 0.05; n = 15).
Figure 4. Acute tubular necrosis (ATN) scores in cisplatin-treated interleukin (IL)-1α -/- mice. By day 3 of cisplatin administration, 
ATN scores were increased significantly in cisplatin-treated wild-type ( 
a,b,cp < 0.05 vs. vehicle-treated wild-type and IL-1α -/- mice, 
cisplatin-treated IL-1α -/- mice, n = 6) and cisplatin-treated IL-1α -/- mice ( 
d,ep < 0.05 vs. vehicle-treated wild-type and IL-1α -/- mice, 
n = 6). Also, there was a significant difference in the ATN scores of cisplatin-treated wild-type vs. cisplatin-treated IL-1α -/- mice (4.7 ± 
0.2 vs. 3.3 ± 0.2; p < 0.05; n = 15). ARF, acute renal failure.
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Figure 5. Neutrophil score in cisplatin-treated interleukin 
(IL)-1α -/- mice. By day 3 of cisplatin administration, neutrophil 
scores had increased significantly in cisplatin-treated wild-type 
(
a,b p < 0.05 vs. vehicle-treated wild-type and IL-1α -/- mice, n = 
15) and cisplatin-treated IL-1α -/- mice (
c,d p < 0.05 vs. vehicle-
treated wild-type and IL-1α -/- mice, n = 15). However, there 
was no significant difference in the neutrophil scores of cisplat-
in-treated wild type and cisplatin-treated IL-1α -/- mice (98.7 ± 
15.1 vs. 90.7 ± 12.5; p > 0.05, n = 15). ARF, acute renal failure.
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Immunofluorescence staining for CD11b- and 
CD49-positive natural killer and natural killer T 
cells in cisplatin-treated IL-1α -/- mice
Infiltration of CD11b-positive cells was significantly 
higher in cisplatin-treated than in vehicle-treated wild-
type and IL-1α -/- mice (10.2 ± 1.3; 10.6 ± 1.0; 1.2 ± 0.2; 
1.4  ±  0.2, p < 0.05, n = 6; Fig. 6). However, there was 
no significant difference in the infiltration of CD11b-
positive cells between cisplatin-treated wild-type and 
IL-1α -/- mice (10.2 ± 1.3; 10.6 ± 1.0; p > 0.05; n = 6). 
The infiltration of CD49b-positive cells was significantly 
higher in cisplatin-treated than in vehicle-treated wild-
type and IL-1α -/- mice (5.7 ± 0.3; 5.2 ± 0.2; 0.4 ± 0.2; 0.7   
±  0.2, p < 0.05; n = 6; Fig. 7), but there was no significant 
difference in the infiltration of CD49b-positive cells 
between cisplatin-treated wild-type and IL-1α -/- mice (5.7 
± 0.3; 5.2 ± 0.2; p > 0.05; n = 6).
Figure 6. Immunofluorescence staining for CD11b (+) cells in cisplatin-treated interleukin (IL)-1α -/- mice. By day 3 of cisplatin ad-
ministration, the infiltration of CD11b (+) cells had increased significantly in cisplatin-treated wild-type ( 
a,bp < 0.05 vs. vehicle-treated 
wild-type and IL-1α -/- mice, n = 6) and IL-1α -/- mice (  
c,dp < 0.05 vs. vehicle-treated wild-type and IL-1α -/- mice, n = 6). However, 
there was no significant difference in the infiltration of CD11b (+) cells between cisplatin-treated wild-type and cisplatin-treated IL-1α 
-/- mice (10.2 ± 1.3; 10.6 ± 1.0; p > 0.05; n = 6).  ARF, acute renal failure.
Figure 7. Immunofluorescence staining for CD49 (+) cells in cisplatin-treated interleukin (IL)-1α -/- mice. By 3 day of cisplatin ad-
ministration, the infiltration of CD49b (+) cells had increased significantly in cisplatin-treated wild-type ( 
a,bp < 0.05 vs. vehicle-treated 
wild-type and IL-1α -/- mice, n = 6) and IL-1α -/- mice ( 
c,dp < 0.05 vs. vehicle-treated wild-type and IL-1α -/- mice, n = 6). However, 
there was no significant difference in the infiltration of CD49b (+) cells between cisplatin-treated wild-type and cisplatin-treated IL-1α 
-/- mice (5.7 ± 0.3; 5.2 ± 0.2; p > 0.05; n = 6). ARF, acute renal failure.
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DISCUSSION
Recently, Faubel et al. [9] demonstrated that caspase-1 -/- 
mice failed to develop cisplatin-induced ARF. Caspase-1, 
formerly known as interleukin-1b converting enzyme, is 
a potent inflammatory agent because of its activation of 
IL-1b, a proximal mediator of the inflammatory events 
associated with infection, sepsis, and ischemia. However, 
a recent study found that although renal IL-1b increased 
prior to the onset of renal dysfunction and was reduced 
in caspase-1 -/- mice, inhibition of the IL-1 receptor did 
not protect against cisplatin-induced ARF. Thus, IL-1b 
does not appear to be an important mediator of cisplatin-
induced ARF. These results are consistent with data from 
other models of ARF, including ischemic and endotoxemic 
ARF [14,15].
In addition to the activation of IL-1b, caspase-1 is 
known to activate the cytokine IL-18, formerly known 
as interferon-gamma-inducing factor. IL-18 is involved 
in a diverse array of functions related to inflammation 
[16]. However, while inhibition of IL-18 protected against 
ischemic ARF [17], IL-18 antiserum failed to prevent 
cisplatin-induced ARF. Moreover, transgenic mice 
overproducing IL-18 binding protein still developed the 
disease [10].
Activated neutrophils may up-regulate adhesion 
molecules, resulting in leukocyte adhesion and the 
obstruction of blood flow in the vasculature, further 
contributing to tubular injury [9]. Although renal 
neutrophils were not detected in mice treated with 
neutrophil-depleting antibody, neither renal function 
nor tubular necrosis improved in the mice with cisplatin-
induced ARF. Thus, while neutrophil recruitment is 
associated with cisplatin-induced ARF, infiltrating 
neutrophils are not essential to the development of tubular 
necrosis and renal failure [10].
Caspase-1 -/- mice are also deficient in IL-1α [11]. Pro-IL-
1α is cleaved to its active form by the calcium-dependent 
cysteine protease calpain. IL-1α lacks the aspartate cleavage 
sequence of caspase-1 and is thus not a substrate for 
the enzyme. Reasons for the reduced levels of IL-1α in 
caspase-1-deficient mice remain unknown. However, no 
protective effect in cisplatin-induced ARF was observed 
in response to inhibitors of IL-1b, IL-18, or neutrophils. 
Thus, in this study we examined whether IL-1α acted as a 
mediator of cisplatin-induced ARF.
Our results showed that cisplatin injection resulted 
in a significant increase in renal IL-1α levels 1 day later, 
thus preceding the increase in IL-1b and IL-18. IL-
1α -/- mice were observed to have less functional and 
histological injury, as judged by serum Cr, BUN, and ATN 
scores. However, there was no difference in the number 
of apoptotic cells between IL-1α -/- and wild-type mice. 
Faubel et al. [9] determined that apoptosis was most severe 
on day 2 after cisplatin injection, while renal dysfunction 
was minimal, suggesting that apoptosis had only a small 
effect on renal dysfunction directly. Alternatively, serum 
Cr and BUN may be inappropriate markers to detect early 
changes in the glomerular filtration rate. Interestingly, 
the reduction in apoptosis on day 2 in caspase-1 -/- mice 
preceded the reduction in necrosis and renal dysfunction, 
both of which occurred on day 3 [9]. This time course of 
events suggests that apoptosis accounts for the necrosis 
and renal dysfunction seen on day 3 [9]. Consistent with 
Faubel’s data is the possibility that the apoptosis noted 
on day 2 resulted in secondary necrosis, which has been 
observed in cisplatin-induced renal tubular injury in vitro 
[2]. Additionally, it has been hypothesized that apoptotic 
and necrotic cell death represent two ends of a response 
continuum [18]. For example, it has been shown in vitro 
that shifts between the two forms of cells death may 
occur, depending on numerous variables, such as growth 
factors [19], oxygen/nutrient availability [20], adenosine 
triphosphate (ATP) concentration [21], and nitric oxide 
[22]. In cisplatin-induced ARF, many factors (e.g., ATP 
reduction) occur that have the potential to promote a shift 
from apoptotic to necrotic cell death [23].
IL-1α, like IL-1b, is a proinflammatory cytokine and 
initiates many of the same biological processes. However, 
IL-1α is unique in that it is not secreted from the cell and 
is rarely found in the extracellular compartment, even 
after activation. Because IL-1α exerts its proinflammatory 
actions either intracellularly or at the cell membrane [24], 
its functions are not inhibited by IL-1Ra. In one report, 
IL-1α was over-expressed in various cells in the presence 
of IL-1Ra, and, despite saturating concentrations of the 
latter, IL-1α activated NF-kB while AP-1 caused IL-8 and 
IL-6 release [24]. Presently, no specific inhibitor of IL-1α is 
available [25].
In this study, we also attempted to identify the mechanism 
by which IL-1α -/- mice are protected against cisplatin-
induced ARF and to determine the role of proinflammatory 
cells in the disease. Thus, we compared the infiltration 
of proinflammatory cells, including neutrophils, CD11b-
positive cells, as a marker of macrophages, and CD49b-
positive cells, as a marker of pan-NK cells, in wild-type Lee JW, et al. IL-1α in cisplatin-induced ARF    193
versus IL-1α -/- mice. Our results showed that there was 
no significant change in the infiltration of neutrophils or in 
CD11b- and CD49b-positive cells between wild-type and 
IL-1α -/- mice. According to our data and those of previous 
studies, neither neutrophil recruitment nor CD11b- and 
CD49b-positive cells are essential for the development of 
cisplatin-induced ARF. Unfortunately, we were unable to 
explain the mechanism underlying the protection of IL-1α 
-/- mice against cisplatin-induced ARF. Recently, Turner et 
al. [26] demonstrated that IL-1α stimulated human cardiac 
myofibroblasts to express proinflammatory cytokines, 
including IL-1b, TNF-α, and IL-6, via specific signaling 
pathways and that these responses are unaffected by IL-
10 exposure. Additionally, TNF-α has been shown to play 
an important role in the pathogenesis of cisplatin-induced 
ARF [27]. Thus, important proinflammatory cytokines, 
such as IL-6 and TNF-α, merit further study in IL-1α -/- 
mice.
We observed that renal IL-1α increased early after 
cisplatin injection and that a deficiency of IL-1α attenuated 
renal dysfunction and tubular necrosis. However, no 
significant difference in neutrophil infiltration, or CD11b- 
and CD49b-positive cells was observed between wild-type 
and IL-1α -/- mice on day 3 after cisplatin administration.
In conclusion, IL-1α -/- mice are protected against 
cisplatin-induced ARF, mimicking the protection against 
cisplatin-induced ARF observed in caspase-1 -/- mice, 
which lack IL-1α. Further investigation of the mechanisms 
that protect IL-1α -/- mice against cisplatin-induced ARF 
is certainly warranted.
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